The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease - Wikidata - awgldk - TriplyDB

The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease

The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease

http://www.wikidata.org/entity/Q37491322

about

Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis Deep brain stimulation for movement disorders Comparison of Globus Pallidus Interna and Subthalamic Nucleus in Deep Brain Stimulation for Parkinson Disease: An Institutional Experience and Review.The cost-effectiveness of deep brain stimulation for patients with treatment-resistant obsessive-compulsive disorder.STN vs. GPi Deep Brain Stimulation: Translating the Rematch into Clinical Practice.Cost-effectiveness of stimulation of the sphenopalatine ganglion (SPG) for the treatment of chronic cluster headache: a model-based analysis based on the Pathway CH-1 study.Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better.Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 2003-2013: Where are we another 10 years on?Deep brain stimulation for Parkinson disease in Australia: current scientific and clinical status.Estimating the direct and indirect costs associated with Parkinson's disease.An economic evaluation of deep brain stimulation for patients with Parkinson's disease.Current Topics in Deep Brain Stimulation for Parkinson Disease.Shaking Up the Debate: Ensuring the Ethical Use of DBS Intervention Criteria for Mid-Stage Parkinson's Patients.Cost-Effectiveness of Deep Brain Stimulation for Advanced Parkinson's Disease in the United States.Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications.The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites.Deep brain stimulation of the subthalamic nucleus: All that glitters isn't gold?The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease

P2860

Q26779605-253BE093-CE34-44F8-983B-EF9D5C9DB5B7 Q30585845-FAB23833-AA6D-4A00-958D-01DA505A557B Q33863693-366DC04D-15AC-4F2D-A7DA-5A0DCA5CFCF8 Q33885834-3B4B48D9-96D7-42DA-871C-635399F887EE Q35159255-291210C8-3233-4041-A8D9-34DF37B0E132 Q35639070-69F99F67-79AD-47CD-BA53-A49BBE9DFB26 Q38250175-321CE442-32DC-4850-8EBE-06F744D4C7AE Q38331824-4110E431-45E5-48F8-B085-5D0F60CB62D2 Q38343742-FF2D7E6A-E6C3-4C64-89F2-87E69359FA72 Q38618871-D45FC92E-7EC0-4AD8-8821-E9BC25B5CF57 Q38871192-74E6F4B6-F680-4634-B3C7-1B56277626C9 Q38878821-52534A83-B76D-4775-B1CA-AB806D0F13E7 Q39301896-887E383C-588E-403D-903B-8CB646768CC8 Q39524073-CB309C7A-6B16-421F-A761-3ED538AB4FB7 Q47679196-0333D479-74C7-4568-A54E-11BE99EC84C3 Q47997995-CCC426B7-31C3-44BB-AFFD-2D3C7802342E Q48065494-DF940D88-152E-42BC-ADEE-BAD042AAB308 Q48345426-683F56CC-EB3F-486D-B06A-0F4FE29E4849 Q58566132-99BBC00D-1FF6-4C5F-9A65-DD7F48920F81

P2860

The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease

http://www.wikidata.org/entity/Q37491322

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The cost-effectiveness of deep ...... n advanced Parkinson's disease

@en

The cost-effectiveness of deep ...... advanced Parkinson's disease.

@nl

type

label

The cost-effectiveness of deep ...... n advanced Parkinson's disease

@en

The cost-effectiveness of deep ...... advanced Parkinson's disease.

@nl

prefLabel

The cost-effectiveness of deep ...... n advanced Parkinson's disease

@en

The cost-effectiveness of deep ...... advanced Parkinson's disease.

@nl

P1433

Q37491322-ACE50540-7615-41BD-914F-479E8420BDCE

P1476

Q37491322-7079CCC1-D5A5-45A2-94BB-01B1E9F1E6D2

P2093

Q37491322-0F3F0182-5AC6-494E-865F-16A4BD470756

Q37491322-745E6B1C-5015-42C0-966F-9E0A18811B87

Q37491322-C5212C8B-D026-4826-9595-579A8B5AE20D

P2860

Q37491322-05FA9ED9-E730-40D8-84B4-D2CF61AA3381

Q37491322-0E71D791-7D3D-4769-A73E-20569ACFDF1D

Q37491322-13EC246E-DAC6-4DE4-9691-F8BFC29BBF10

Q37491322-18522A6E-B6AE-44FC-95AA-2604DCB4CF04

Q37491322-1E3E5A08-50C8-4AB1-8E4E-CC4299BEC4F2

Q37491322-2063E663-D3A9-48E4-B882-95437DF30E2C

Q37491322-25C6FC77-FA28-41FD-8B41-F461FFD75B07

Q37491322-29BF53B2-D835-4ACD-9666-F10304C3EDF7

Q37491322-2CEB4A5F-889C-4D46-A3D0-22FF99E650C8

Q37491322-304C92CF-29E7-492C-BB69-F4A59C92D33A

P2888

Q37491322-929C7563-48C3-4A47-B9BC-449076867F6E

P304

Q37491322-54A3F3A7-A0BF-4CB9-B04C-887812A0F90E

P31

Q37491322-76E3E7BA-20BA-4BA9-8FB0-889E5CC39578

P356

Q37491322-3720CDAC-AE7E-4092-8FB6-3970DD63EA92

P433

Q37491322-7630E839-C178-41AB-9BA4-C371FA95576F

P478

Q37491322-6604FDBC-108B-4297-BB98-AC2B0CCF185A

P50

Q37491322-12EE1EA0-D060-4AE0-8464-5A66BB260100

Q37491322-3A4E0D57-98BC-449D-9F76-CA86574E0515

Q37491322-4DF85278-A694-4B82-96E7-DE9369AA7AD0

P577

Q37491322-22ADFEFA-7EC8-4A24-8309-E76F04182978

P5875

Q37491322-4D8C7FAD-B3AF-47FE-AB4D-3E2E09675C6F

P698

Q37491322-1E0E738B-4C79-4A5E-9126-F7D621193390

P921

Q37491322-1D1D902E-9DB9-4EF9-84FC-AEB457E80E0E

Q37491322-6D85A79C-1F75-410A-A852-9ED672D80F90

P932

Q37491322-05326943-BD57-4894-94BE-6D144B2B6E84

P356

S00415-013-7148-Z

P1433

Journal of Neurology

P1476

The cost-effectiveness of deep ...... n advanced Parkinson's disease

@en

P2093

Elena Annoni

http://www.w3.org/2001/XMLSchema#string

Keyoumars Ashkan

http://www.w3.org/2001/XMLSchema#string

Simon Eggington

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinsonism: onset, progression and mortality

Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'

Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial.

Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial.

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial

Resource use and costs in a Swedish cohort of patients with Parkinson's disease.

The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years

What contributes to quality of life in patients with Parkinson's disease?

P2888

s00415-013-7148-z

P304

106-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00415-013-7148-Z

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

261

http://www.w3.org/2001/XMLSchema#string

P50

Günther Deuschl

Kallol Ray Chaudhuri

Francesc Valldeoriola

P577

2013-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258043694

http://www.w3.org/2001/XMLSchema#string

P698

24158271

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

deep brain stimulation

P932

3895185

http://www.w3.org/2001/XMLSchema#string